OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Smith on Using Venetoclax Versus Ibrutinib in CLL

October 17th 2019

Mitchell R. Smith, MD, PhD, discusses the use of venetoclax versus ibrutinib in patients with chronic lymphocytic leukemia.

Dr. Concepcion on Barriers to Genetic Testing in Community Urology Practices

October 17th 2019

Raoul S. Concepcion, MD, FACS, discusses barriers to genetic testing for patients with prostate cancer as identified by community urologists.

Dr. George on Investigational Agents Downstream of the Androgen Receptor in Prostate Cancer

October 17th 2019

Daniel J. George, MD, discusses investigational agents downstream of the androgen receptor in advanced prostate cancer.

Dr. Bourhis on the Rationale to Explore Debio 1143 in Head and Neck Cancer

October 17th 2019

Jean Bourhis, MD, PhD, Radiation Oncology, Centre Hospitalier Universitaire Vaudois, discusses the rationale to explore Debio 1143 in patients with head and neck cancer.

Dr. Lee on Trial Data Evaluating the Atezolizumab/Bevacizumab in Unresectable HCC

October 17th 2019

Michael S. Lee, MD, discusses trial data evaluating the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in unresectable hepatocellular carcinoma.

Dr. Mato on the Use of Biosimilars in CLL

October 17th 2019

Anthony R. Mato, MD, MSCE, discusses the use of biosimilars in chronic lymphocytic leukemia.

Dr. Kuykendall on Choosing Ruxolitinib or Fedratinib in Myelofibrosis

October 17th 2019

Andrew T. Kuykendall, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis.

Dr. Schiller on Venetoclax and Glasdegib in AML

October 17th 2019

Gary J. Schiller, MD, discusses the benefits and challenges of using venetoclax and glasdegib in patients with relapsed/refractory acute myeloid leukemia.

Dr. Grande on the IMvigor130 Trial in Metastatic Urothelial Cancer

October 17th 2019

Enrique Grande, MD, discusses the design of the phase III IMvigor130 trial, which compared atezolizumab plus chemotherapy versus atezolizumab monotherapy (arm B) versus standard chemotherapy plus placebo in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Dr. Gerson on Targeted Therapy Versus Chemotherapy in CLL

October 16th 2019

James N. Gerson, MD, discusses the emergence of targeted therapy in chronic lymphocytic leukemia.

Dr. Lee on the Results of the ENTRATA Trial in Advanced RCC

October 16th 2019

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Dr. Bhave on Promising Anti-HER2 Agents in HER2+ Breast Cancer

October 16th 2019

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

Dr. Nasri on Risk Stratification in Osteosarcoma

October 16th 2019

Elham Nasri, MD, fellow, Bone and Soft Tissue Pathology, University of Florida, discusses risk stratification in osteosarcoma.

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

October 15th 2019

Tanios S. Bekaii-Saab, MD, FACP, discusses the results of the phase II BACCI trial evaluating the addition of atezolizumab to capecitabine plus bevacizumab versus capecitabine/bevacizumab plus placebo in patients with microsatellite stable metastatic colorectal cancer.

Dr. Shroff on Genomic Landscape of Cholangiocarcinoma

October 15th 2019

Rachna T. Shroff, MD, MS, discusses actionable targets in intrahepatic and extrahepatic cholangiocarcinoma.

Dr. Mato on Utilizing CAR T Cells in CLL

October 15th 2019

Anthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.

Dr. Gupta on Challenges of Identifying Biomarkers in Bladder Cancer

October 15th 2019

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Dr. Kerrigan on Design and Findings of the PROFILE 1001 Trial in ROS1-Mutated NSCLC

October 15th 2019

Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses the design and findings of the ongoing phase I PROFILE 1001 trial with crizotinib (Xalkori) in ROS1-mutated non–small cell lung cancer (NSCLC).

Dr. Gerson on Strategies Aimed at Alleviating Toxicity in Older Patients With MCL

October 15th 2019

James N. Gerson, MD, assistant professor of clinical medicine, Perelman School of Medicine, University of Pennsylvania, discusses strategies aimed at alleviating toxicity in older patients with mantle cell lymphoma (MCL).

Dr. Atkins on Long-Term Outcomes of the CheckMate-204 Trial in Melanoma

October 15th 2019

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.